500mg Fulvestrant Versus Exemestane in MBC

Completed

• Conditions: Breast Cancer

• Registration Number: NCT03575260
• Lead Sponsor: Fudan University

Brief Summary

500mg Fulvestrant versus Exemestane in MBC

Detailed Description

500mg Fulvestrant versus Exemestane in Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors in clinical practice- a multicenter retrospective study

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2017-07-01
• Study First Submitted: 2018-06-21
• Study First Submitted QC: 2018-06-21
• Study First Posted: 2018-07-02
• Primary Completion: 2019-01-10
• Study Completion: 2019-01-15
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-29
• Last Update Posted: 2019-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

• Postmenopausal woman, age > 18 years old
• Diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
• Adjuvant treatment of Non-steroidal Aromatase Inhibitors
• First line of Metastatic Breast Cancer is 500mg Fulvestrant or Exemestane for at least one month, starting from 2014.01.01-2017.06.01
• Available medical history

Read More

Exclusion Criteria

• Incomplete medical history

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	6 weeks	Progression free survival

Secondary Outcome Measures

Name	Time	Method
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	6 weeks

Trial Locations

Locations (1)

Biyun Wang, MD; 🇨🇳 Shanghai, Shanghai, China